Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with and without statin therapy for rivaroxaban and enoxaparin/VKA combined

From: Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy

Characteristic Patients treated with statins (n=1509) Patients not treated with statins (n=6731) p-value
Mean age, years 66.5 54.9 <0.01
Men, n (%) 847 (56.1) 3650 (54.2) 0.18
Mean BMI, kg/m2 29.3 27.8 <0.01
Creatinine clearance, n (%)    <0.01
 <50 ml/min 207 (13.7) 442 (6.6)  
 50–<80 ml/min 515 (34.1) 1500 (22.3)  
 ≥80 ml/min 775 (51.4) 4736 (70.4)  
 Missing 12 (0.8) 53 (0.8)  
Planned treatment duration, n (%)    <0.01
 3 months 75 (5.0) 580 (8.6)  
 6 months 858 (56.9) 4056 (60.3)  
 12 months 576 (38.2) 2095 (31.1)  
Index event, n (%)    <0.01
 Only DVT 489 (32.4) 2880 (42.8)  
 PE ± DVT 1012 (67.1) 3783 (57.2)  
 Index event not confirmed or evaluable 8 (0.5) 68 (1.0)  
Immobilization at randomization, n (%) 232 (15.4) 1051 (15.6) 0.82
Active cancer at randomization, n (%) 76 (5.0) 352 (5.2) 0.76
Ischemic heart disease, n (%) 410 (27.2) 229 (3.4) <0.01
Peripheral arterial disease, n (%) 39 (2.6) 29 (0.4) <0.01
Ischemic cerebrovascular disease, n (%) 53 (3.5) 45 (0.7) <0.01
ASA use at baseline, n (%) 387 (26.5) 337 (5.0) <0.01
ASA stopped at randomization, n 85 122  
Hypertension, n (%) 1052 (69.7) 2181 (32.4) <0.01
Diabetes, n (%) 392 (26.0) 512 (7.6) <0.01
  1. ASA, acetylsalicylic acid; BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; VKA, vitamin K antagonist.
  2. Data from EINSTEIN DVT and EINSTEIN PE combined, safety population.